Biopharmaceutical News and Research

RSS

Global Genes Project: World Rare Disease Day 2010, a tremendous success

The Global Genes Project, a worldwide rare disease awareness initiative, today announced the success from its World Rare Disease Day 2010 efforts and laid out plans for future rare disease awareness campaigns.

8 Mar 2010

Quintiles opens expanded research facility in London

Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

8 Mar 2010

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.

8 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

AMICAS and Merge Healthcare sign definitive merger agreement

AMICAS, Inc. and Merge Healthcare Incorporated (Nasdaq: MRGE) today announced that they will enter into a definitive merger agreement pursuant to which Merge will acquire all of the outstanding shares of AMICAS for $6.05 per share in cash, or an aggregate of $248 million.

5 Mar 2010

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

During a meeting with the investment community today, Bristol-Myers Squibb Company will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.

5 Mar 2010

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

An article in the Glencoe Enterprise recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

5 Mar 2010

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Repligen acquires BioFlash

Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.

4 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with Harvard University and the Howard Hughes Medical Institute to provide their researchers with the LEAP™ Cell Processing Workstation.

3 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Pi2 Solutions introduces 2010 version of Product Literature Database System

Pi2 Solutions announces the all-new 2010 version of their world-leading Product Literature Database System. This versatile application builds on the success of the 2003 version in use in biopharmaceutical companies around the globe.

1 Mar 2010

Biopharmaceutical News and Research

Global Genes Project: World Rare Disease Day 2010, a tremendous success

Quintiles opens expanded research facility in London

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

AMICAS and Merge Healthcare sign definitive merger agreement

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Repligen acquires BioFlash

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Cyntellect to provide LEAP Cell Processing Workstation to Harvard University and HHMI researchers

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

Archimedes Pharma raises GBP65 million in new funding

AMAG Pharmaceuticals reports fourth-quarter 2009 net product revenues of $12.8M attributable to Feraheme

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Pi2 Solutions introduces 2010 version of Product Literature Database System

Event guide: 3rd EHS for Biopharma Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News